enhertu cost
![Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients](https://pharmtales.com/wp-content/uploads/2023/07/Enhertu-Receives-Approval-in-China-as-Groundbreaking-HER2-Directed-Therapy-for-HER2-Low-Metastatic-Breast-Cancer-Patients.jpg)
Enhertu Receives Approval in China as Groundbreaking HER2-Directed Therapy for HER2-Low Metastatic Breast Cancer Patients
SG Tylor
Source – AstraZeneca Enhertu (trastuzumab deruxtecan), a targeted antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, has received approval ...